Intravesical Bleomycin in Bladder Cancer

Publisher Website
Google Scholar
Abstract
To the Editor.— In a recent letter to the editor (235:906, 1976), Smith and McCollum reported on the results they obtained with intravesically administered bleomycin. The authors concluded (1) that bleomycin, 30 units, given intravesically weekly for eight weeks did not demonstrate significant activity, and (2) that bleomycin was absorbed from the bladder to a significant degree. We have studied 26 patients with stage O-A bladder cancers who would otherwise have been candidates for thiotepa therapy. Our results, which will be published in full shortly, indicate that bleomycin at a dose of 30 units weekly is not active, but at doses of 60 units weekly or greater, it is active in the treatment of bladder cancers. Responses (greater than 50% reduction in tumor size) have been noted in 7/18 patients treated with 60 or more units of bleomycin given intravesically. However, responses are no greater than we would have expected

This publication has 0 references indexed in Scilit: